CRISPR Therapeutics AG (NASDAQ:CRSP) - Investment analysts at Oppenheimer issued their Q1 2021 earnings estimates for CRISPR Therapeutics in a report released on Wednesday, April 21st. Oppenheimer analyst J. Olson forecasts that the company will post earnings of ($1.37) per share for the quarter. Oppenheimer currently has a "Outperform" rating and a $187.00 target price on the stock. Oppenheimer also issued estimates for CRISPR Therapeutics' Q2 2021 earnings at ($1.43) EPS and Q4 2021 earnings at ($1.39) EPS.
Other research analysts have also recently issued research reports about the company. TheStreet cut CRISPR Therapeutics from a "c-" rating to a "d" rating in a research note on Wednesday, March 10th. Needham & Company LLC reissued a "buy" rating on shares of CRISPR Therapeutics in a research report on Wednesday, February 17th. Jefferies Financial Group raised shares of CRISPR Therapeutics from a "hold" rating to a "buy" rating and set a $172.00 price objective for the company in a research report on Wednesday. Chardan Capital boosted their target price on shares of CRISPR Therapeutics from $166.00 to $175.00 and gave the stock a "buy" rating in a research report on Wednesday, February 17th. Finally, JMP Securities started coverage on shares of CRISPR Therapeutics in a report on Wednesday, March 10th. They set an "outperform" rating and a $160.00 price target for the company. Three analysts have rated the stock with a sell rating, three have assigned a hold rating and thirteen have assigned a buy rating to the stock. The company presently has an average rating of "Buy" and an average target price of $161.82.
NASDAQ:CRSP opened at $124.93 on Thursday. CRISPR Therapeutics has a twelve month low of $46.84 and a twelve month high of $220.20. The firm has a market capitalization of $9.42 billion, a price-to-earnings ratio of -38.32 and a beta of 2.37. The firm's fifty day simple moving average is $121.16 and its 200 day simple moving average is $134.63. CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Monday, February 15th. The company reported ($1.50) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.23). CRISPR Therapeutics had a negative return on equity of 20.72% and a negative net margin of 273.10%. The company had revenue of $0.37 million for the quarter, compared to analyst estimates of $4.69 million.
In other CRISPR Therapeutics news, Director Bradley J. Phd Bolzon sold 30,374 shares of CRISPR Therapeutics stock in a transaction on Monday, March 22nd. The shares were sold at an average price of $132.37, for a total value of $4,020,606.38. Following the completion of the transaction, the director now owns 57,149 shares of the company's stock, valued at $7,564,813.13. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 17.10% of the company's stock.
Several institutional investors have recently bought and sold shares of CRSP. Norges Bank bought a new position in shares of CRISPR Therapeutics in the 4th quarter worth about $86,215,000. Morgan Stanley increased its holdings in shares of CRISPR Therapeutics by 45.3% in the 4th quarter. Morgan Stanley now owns 731,427 shares of the company's stock worth $111,988,000 after acquiring an additional 227,927 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in shares of CRISPR Therapeutics by 8.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,774,436 shares of the company's stock worth $271,684,000 after acquiring an additional 143,504 shares during the period. Nikko Asset Management Americas Inc. increased its holdings in shares of CRISPR Therapeutics by 3.8% in the 4th quarter. Nikko Asset Management Americas Inc. now owns 3,836,823 shares of the company's stock worth $587,456,000 after acquiring an additional 139,156 shares during the period. Finally, Hitchwood Capital Management LP acquired a new stake in shares of CRISPR Therapeutics in the 4th quarter worth about $11,483,000. Institutional investors own 66.43% of the company's stock.
CRISPR Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA.
Featured Story: What Is Dividend Yield and How Do You Calculate It?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: Portfolio Manager
Like any group of stocks related to travel and tourism, hotel stocks saw a steep drop in share prices in 2020. The leisure and hospitality sector that once had 15 million employees has lost 4 million jobs since February.
Many major cities will be feeling the ripple effects of the Covid-19 pandemic for years. However, there is ample evidence that shows the pandemic may be coming to an end. The number of new cases is dropping. The number of those getting vaccinated is rising. And even in the cities with the most restrictive mitigation measures, the slow process of reopening is beginning.
All of this can’t come fast enough for individuals who rely on the travel and tourism industry for their livelihood. Hotel chains had at least some revenue coming in the door. And when earnings season concludes, the more budget-friendly hotel chains may realize revenue that is 75% of its 2019 numbers. But that is not enough to bring the hotels to anywhere near full employment. Particularly with hotels that have bars and restaurants that have remained closed or open at limited capacity.
Many economists are optimistic that travel may begin to look more normal by the summer of this year. And the global economy may deliver 6.4% GDP growth this year. With that in mind, the hotel chains with the best fundamentals and the broadest footprint will be in the best position as the economy reopens.